医疗科技初创公司Science Corporation宣布完成4亿美元的D轮融资,使其估值达到35亿美元 1。该公司由前Neuralink总裁Max Hodak于2021年创立,本轮融资得到了Khosla Ventures、Ackman Oxman Institute、Tenet Healthcare、885 Capital、Y Combinator以及PLC Neurotech等多家机构的支持 1。
资金将主要用于推动其首款产品PRIMA进入美国市场,并加速开发基于培养神经元和硅的生物混合传感器以直接连接人脑 1。PRIMA是一款结合了可穿戴和植入式技术的芯片,旨在帮助老年黄斑变性患者恢复视力,目前已获批在欧洲(德国)使用,并正针对Stargardt病进行试验 1。该公司计划通过美国食品药品监督管理局(FDA)的人道主义器械豁免途径将该设备引入美国 1。此外,Science Corporation正在与耶鲁大学教授Murat Günel合作设计生物混合传感器,该技术的潜在应用领域包括帕金森病的治疗 1。
Science Corporation, a medical technology startup founded by former Neuralink president Max Hodak in 2021, has completed a $400 million Series D funding round that places the company’s valuation at $3.5 billion 1. The investment was supported by a group of backers including Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech 1.
The newly acquired capital will primarily fund the entry of the company’s first product, PRIMA, into the United States market via the FDA’s Humanitarian Device Exemption pathway 1. PRIMA is a wearable and implantable chip designed to restore vision for patients with age-related macular degeneration; it has already received approval for use in Europe (Germany) and is currently undergoing trials for Stargardt's disease 1. Additionally, Science Corporation plans to accelerate the development of biohybrid sensors that connect directly to the human brain by combining cultured neurons with silicon 1. In this area, the company is collaborating with Yale University professor Murat Günel to design human trials for these sensors, which hold potential applications for treating Parkinson's disease 1.
评论
还没有评论,欢迎留下第一条。